Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73 price target The firm says Newron is developing a first-in-class drug, evenamide for treatment-resistant schizophrenia. It sees blockbuster potential for the drug.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NWPHF:
- Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
- Newron Pharma initiated with a Buy at H.C. Wainwright
- Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment
- Newron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant Schizophrenia